PTC Therapeutics traded at $40.40 this Wednesday June 29th, increasing $0.46 or 1.15 percent since the previous trading session. Looking back, over the last four weeks, PTC Therapeutics gained 37.56 percent. Over the last 12 months, its price fell by 4.42 percent. Looking ahead, we forecast PTC Therapeutics to be priced at 39.14 by the end of this quarter and at 36.06 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 3,419.00 22.00 0.65% 42.79%
Acadia Pharmaceuticals 14.22 0.22 1.57% -41.70%
Alnylam Pharmaceuticals 145.43 3.23 2.27% -14.21%
Amgen 245.43 1.92 0.79% 0.69%
BioCryst Pharmaceuticals 10.81 0.35 3.35% -31.63%
Biogen 205.23 2.72 1.34% -40.73%
Bluebird Bio 4.58 0.54 13.37% -85.68%
BioMarin Pharmaceutical 83.92 0.77 0.93% 0.58%
Cytokinetics 48.74 1.44 3.04% 146.29%
Enanta Pharmaceuticals 46.91 2.36 5.30% 6.59%
Esperion Therapeutics 6.67 0.40 6.38% -68.46%
Gilead Sciences 62.48 0.27 0.43% -9.27%
Intercept Pharmaceuticals 13.67 0.67 5.15% -31.55%
Incyte Corp 75.89 0.26 0.34% -9.79%
Ionis Pharmaceuticals 37.56 -0.41 -1.08% -5.84%
Ironwood Pharmaceuticals 11.72 0.19 1.65% -8.94%
Karyopharm Therapeutics 4.51 -0.07 -1.53% -56.30%
Novartis 81.19 0.05 0.06% -3.71%
Puma Biotechnology 2.85 0.07 2.52% -68.95%
Pfizer 50.94 0.28 0.55% 30.08%
PTC Therapeutics 40.40 0.46 1.15% -4.42%
Ultragenyx Pharmaceutical 60.24 1.51 2.57% -36.82%
Roche Holding 319.65 2.10 0.66% -8.29%
Sangamo BioSciences 4.14 0.05 1.22% -65.41%
Sarepta Therapeutics 77.07 2.40 3.21% -0.86%
TG Therapeutics 4.32 0.26 6.40% -88.86%
Vertex Pharmaceuticals 280.35 4.18 1.51% 38.64%
Xencor 27.20 0.14 0.52% -21.14%

Indexes Price Day Year
USND 11178 -3.65 -0.03% -22.93%
US2000 1719 -19.47 -1.12% -25.59%

PTC Therapeutics
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).